Quest PharmaTech Inc. (CVE:QPT), a pharma stock, climbed after its subsidiary announced interim results
Sean Mason | November 30, 2016 | SmallCapPower
A clinical study announcement sparked speculation in a pharma stock Wednesday. Here’s some small stocks making big moves on Wednesday, November 30, 2016 (as of 4 pm EST):
Pharma stock Quest PharmaTech Inc. (CVE:QPT) jumped 72% to $0.155 on Wednesday after announcing that its subsidiary, OncoQuest Inc., revealed what it called “positive” interim results from the Phase 2b clinical study of its lead product, oregovomab, in patients with advanced epithelial ovarian, adnexal or peritoneal carcinoma.
As well, shares of Delivra Corp. (CVE:DVA) gained 16% to $0.59 as the specialty biotechnology company said its third-quarter revenue increased 42% to a record $630,265. The Company added that it has completed a licensing agreement with Canopy Growth Corporation for the transdermal delivery of medical cannabis.
Nevada Zinc Corporation (CVE:NZN), meanwhile, reported that it has outlined what it called a “significant gold exploration target” on its VIP Project located in Yukon, west of Goldcorp’s Coffee Gold Project. Nevada Zinc stock moved up 8% to $0.52 following the announcement.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
